NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025)
NovaBridge Biosciences (NBP) reported Net Income towards Common Stockholders of -$72.9 million for Q4 2025, down 112.02% year-over-year from $606.2 million in Q4 2024, and down 967.05% quarter-over-quarter from -$6.8 million in Q3 2025.
NovaBridge Biosciences (NBP) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$72.9 million in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$72.9 million, down 112.02% year-over-year; the trailing twelve-month figure through Dec 2025 was -$88.3 million (down 141.19% YoY), and the FY2024 annual result was -$6.9 million, up 96.66% from the prior year.
- Net Income towards Common Stockholders eased to -$72.9 million in Q4 2025 per NBP's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $33.3 million in Q3 2023 and troughed at -$72.9 million in Q4 2025.
- A 3-year average of -$15.3 million and a median of -$6.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 140.88% in 2024 and fell as far as 161.62% in 2024.
- A 3-year view of Net Income towards Common Stockholders shows it stood at $33.3 million in 2023, then slumped by 203.33% to -$34.4 million in 2024, then sank by 112.02% to -$72.9 million in 2025.
- Business Quant data shows NBP's Net Income towards Common Stockholders at -$72.9 million in Q4 2025, -$6.8 million in Q3 2025, and -$5.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | -72.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.86 Mn |
| Sep 30, 2025 | -6.83 Mn |
| Jun 30, 2025 | -5.50 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -20.49 Mn |
| Jun 30, 2024 | 25.13 Mn |
| Mar 31, 2024 | -6.90 Mn |
| Sep 30, 2023 | 33.26 Mn |
| Jun 30, 2023 | -61.47 Mn |
| Dec 31, 2020 | 157.16 Mn |
| Sep 30, 2020 | -82.36 Mn |
| Dec 31, 2019 | -54.14 Mn |
| Sep 30, 2019 | -35.10 Mn |